Our website uses cookies to distinguish you from other users of our site. This helps us to continually improve your experience when using our website. We also use external analytics software which may set additional cookies to perform their analysis. These cookies (and any others in use) are detailed in our site Privacy and Cookie Policies. You can delete or disable these cookies in your web browser at any time but doing so may impact website functionality and user experience.

Dr Iain Thomas Dr Iain Thomas Interim Head of Technology Transfer
Iain is Interim Head of Technology Transfer at Cambridge Enterprise.


He is also Head of Life Sciences at Cambridge Enterprise, responsible for a team that is working across the life sciences sector from human health therapeutics to agritech and research tools. Iain has a PhD in Organic Chemistry (Sydney) and MBA (Cambridge).

The team has spun-out companies including X01 Therapeutics, Apcintex (now a Centessa company), DIOSynVax, NoBACZ Healthcare, Predictimmune Limited, PhoreMost, Z-factor and Cambridge Epigenetix. Iain, with colleagues from partner universities founded Apollo Therapeutics, a £40 million fund in early stage drug development and launched the Ceres Agritech Knowledge Exchange Partnership. Iain also led discussions with GSK in respect of the University of Cambridge-GSK open innovation drug discovery initiative based at the Stevenage Bioscience Catalyst.

Iain joined Cambridge Enterprise in November 2003.